SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: drdan who wrote (2853)7/8/1998 9:30:00 PM
From: dwlima  Read Replies (1) | Respond to of 5402
 
in which phase did entremed get their big stock appreciatio? from what i have read, even if sgnc has a small chance at having a successful product, it is worth a few dollars. but, you are right, people are waiting for the proof....i thought batelle was a big, ringing endorsement and that the investment community would rely on their expertise at evaluating these products. what do you think?



To: drdan who wrote (2853)7/8/1998 10:25:00 PM
From: Mr. Forthright  Respond to of 5402
 
<<This one has little interest now because most people in the investment community don't have the medical background to appreciate products such as these...>>

That is right, the biotech analyst at Merrill Lynch actually only has a Liberal Arts degree.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News